Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
All vitamin C studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin CVitamin C (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI)

Fowler et al., NCT04344184, SAFE EVICT CORONA-ALI, NCT04344184
Apr 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 19% Improvement Relative Risk WHO status -2% Vitamin C  SAFE EVICT CORONA-ALI  ICU PATIENTS  DB RCT Is very late treatment with vitamin C beneficial for COVID-19? Double-blind RCT 47 patients in the USA Trial underpowered to detect differences c19early.org Fowler et al., NCT04344184, April 2024 Favorsvitamin C Favorscontrol 0 0.5 1 1.5 2+
Vitamin C for COVID-19
6th treatment shown to reduce risk in September 2020
 
*, now with p = 0.000000038 from 71 studies, recognized in 12 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19early.org
RCT 47 ICU patients showing no significant differences with vitamin C treatment.
Although the 19% lower mortality is not statistically significant, it is consistent with the significant 19% lower mortality [9‑27%] from meta analysis of the 42 mortality results to date.
This is the 21st COVID-19 RCT for vitamin C, which collectively show efficacy with p=0.0012.
This is the 70th of 71 COVID-19 controlled studies for vitamin C, which collectively show efficacy with p=0.000000038 (1 in 26 million).
This study is excluded in the after exclusion results of meta analysis: very late stage, ICU patients.
risk of death, 18.8% lower, RR 0.81, p = 0.75, treatment 5 of 22 (22.7%), control 7 of 25 (28.0%), NNT 19.
relative WHO status, 1.7% worse, RR 1.02, p = 0.28, treatment mean 3.05 (±0.218) n=21, control mean 3.0 (±0.0) n=23, day 27.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Fowler et al., 4 Apr 2024, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, trial NCT04344184 (history) (SAFE EVICT CORONA-ALI).
This PaperVitamin CAll
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit